Joint implants should always be made of materials like titanium, so they can last the lifetime of the patient ... right? Well, not according to researchers at Finland's Tampere University of Technology. They've developed a product known as RegJoint, which is reportedly the world's first biodegradable joint implant. Unlike permanent implants, it allows the patient's bone ends to remain intact, and it creates a new joint out of their own tissue.
In arthritic joints, the cartilage that protects the connecting ends of the bones has become compromised. This allows the bones themselves to grate against one another, causing pain and reducing the joint's range of movement. A traditional permanent implant replaces the ends of the affected bones with low-friction man-made material.
UPGRADE TO NEW ATLAS PLUS
More than 1,500 New Atlas Plus subscribers directly support our journalism, and get access to our premium ad-free site and email newsletter. Join them for just US$19 a year.UPGRADE
RegJoint, however, takes a different approach.
The implant has been in development since the mid 90s, and is intended for use in the small finger and toe joints of osteoarthritis and rheumatoid arthritis patients. It is made from a polylactide copolymer, and is inserted within the joint capsule of the affected digit.
Once in place, it reduces pain by acting as a cushioning spacer between the exposed bone ends, while also also restoring a reasonable range of movement, and keeping the already-compromised cartilage from being damaged further. Additionally, however, it triggers the body to produce new fibrous tissue, which proceeds to gradually replace the implant. According to the university, all that's left eventually is a fully-functioning "neojoint," made from the body's own cells.
Recently, RegJoint received CE Mark approval, which will allow it to be sold within Europe - it has already been used in over 200 patients, in clinical trials. Assisting in its development were Conmed Linvatec Biomaterials and Scaffdex Ltd., which is now bringing the implant to market.
Source: Tampere University of Technology